Pfizer has transferred global rights for the VEPPANU drug to Rigel Pharmaceuticals, maintaining an economic stake amid growing financial pressures. The company anticipates a revenue decline of approximately $1.5 billion in 2026 due to product exclusivity losses, with projected total revenues between $59.5 billion and $62.5 billion, down from $62.6 billion in 2025. Despite these challenges, Pfizer's stock has risen by 4.3% this year, though its forward earnings remain notably lower than the industry average.
“Pfizer · transferred · global development and commercialization rights for VEPPANU · to Rigel Pharmaceuticals”
“Pfizer · retains · an economic interest · through the deal structure”
“one key risk · is that · Pfizer already faces pressure on earnings”
“Pfizer · carries · a dividend · that analysts flag as not well covered by cash flow”
“Pfizer · is conducting · the BASIS KIDS study · investigating the safety and efficacy of HYMPAVZI in children <18 years of age”
“Rigel · has entered into · exclusive global license agreement · with Arvinas and Pfizer”
“Arvinas and Pfizer · will receive · an upfront payment of $70.0 million and an additional $15.0 million · upon successful completion of certain development and manufacturing transition activities”
“Pfizer · acquisition of · Seagen · true”
“Pfizer · expects · high single-digit 5-year revenue CAGR · starting from 2029”
“Pfizer · 2025 revenues fell · $62.6 billion · 2%”
“Pfizer · expects total revenues in 2026 · between $59.5 billion and $62.5 billion”
“Pfizer · expects significant negative impact on revenues · from loss of exclusivity in 2026-2030”
.svg&width=160)